Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners dropped their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 15.9 %

Shares of NASDAQ:AWH opened at $0.91 on Monday. Aspira Women’s Health has a twelve month low of $0.74 and a twelve month high of $6.01. The stock’s 50 day moving average is $0.93 and its 200-day moving average is $1.76. The firm has a market capitalization of $14.60 million, a price-to-earnings ratio of -0.63 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter last year, the firm posted ($0.28) EPS. Equities research analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.